ArticleNature reviews. Gastroenterology & hepatology2022
Natural history of NAFLD: knowns and unknowns.
Article in Nature reviews. Gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07430501 (AcceleRating the Translation of Virtual Twins Towards a pErsonalised Management of Steatotic Liver Patients), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AcceleRating the Translation of Virtual Twins Towards a pErsonalised Management of Steatotic Liver Patients
Who cites it
15 citing papers in PubMed.
- Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals.World journal of hepatology · 2026Article
- MicroRNA-21 is a potential therapeutic agent targetingMolecular therapy. Nucleic acids · 2025Article
- Food-derived bioactive peptides: health benefits, structure‒activity relationships, and translational prospects.Journal of Zhejiang University. Science. B · 2025Review
- Article
- Gut microbiota and its derived metabolites as silent sculptors of non-alcoholic fatty liver disease development and potential guide for non-invasive clinical diagnostics.Molecular biology reports · 2025Review
- Disrupted host-microbiota crosstalk promotes nonalcoholic fatty liver disease progression by impaired mitophagy.Microbiology spectrum · 2025Article
- Incremental Value of Blood-Based Markers of Liver Fibrosis in Cardiovascular Risk Stratification.The Journal of clinical endocrinology and metabolism · 2025Article
- Mechanism of swertiamarin and novel nitrogen-containing metabolites (Frontiers in pharmacology · 2025Article
- miR-21: A therapeutic target for delaying severe liver disease and hepatocellular carcinoma in high-fat-diet-fed mice.bioRxiv : the preprint server for biology · 2024Article
- Strong associations between fasting lipids and glucose concentrations and ALT levels strengthened with increasing ALT quantiles.Lipids in health and disease · 2024Article
- Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes.Frontiers in immunology · 2024Review
- Active role of the immune system in metabolic dysfunction-associated steatotic liver disease.Gastroenterology report · 2024Review
- MicroRNA regulation of AMPK in nonalcoholic fatty liver disease.Experimental & molecular medicine · 2023Review
- Impact ofAnnals of medicine · 2023Review
- PMEnvironmental research · 2022Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34880412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.